Medical device company Boston Scientific (NYSE:BSX) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 20.9% year on year to $4.66 billion. Guidance for next quarter’s revenue was better than expected at $4.88 billion at the midpoint, 2% above analysts’ estimates. Its non-GAAP profit of $0.75 per share was 11.5% above analysts’ consensus estimates.
Boston Scientific (BSX) Q1 CY2025 Highlights:
Revenue: $4.66 billion vs analyst estimates of $4.57 billion (20.9% year-on-year growth, 2% beat)
Adjusted EPS: $0.75 vs analyst estimates of $0.67 (11.5% beat)
Revenue Guidance for Q2 CY2025 is $4.88 billion at the midpoint, above analyst estimates of $4.79 billion
Management raised its full-year Adjusted EPS guidance to $2.91 at the midpoint, a 2.5% increase
Operating Margin: 19.8%, up from 17.5% in the same quarter last year
Organic Revenue rose 18.2% year on year (13.1% in the same quarter last year)
Market Capitalization: $140.6 billion
"We delivered an exceptional quarter to start the year, reflecting the effectiveness of our highly engaged global team and the strength of our product portfolio," said Mike Mahoney, chairman and chief executive officer, Boston Scientific.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.